 |
recombinant human acid a-glucosidase co-administered with N-butyl-deoxynojirimycin (reconbinant human acid a-glucosidase/miglustat) |
|---|---|
| Trade Name | |
| Orphan Indication | Pompe disease |
| USA Market Approval | USA |
| USA Designation Date | 2017-09-13 00:00:00 |
| Sponsor | Amicus Therapeutics, Inc.;1 Cedarbrook Drive;Cranbury Township, New Jersey, 08512 |
